Corvus Pharmaceuticals (CRVS) Corporate presentation summary

Strategic positioning and pipeline

• Focus on soquelitinib, a first-in-class, highly selective oral ITK inhibitor with broad potential in immune diseases and oncology.

• Demonstrated safety and efficacy in placebo-controlled Phase 1 atopic dermatitis (AD) trial; Phase 2 AD and registration Phase 3 PTCL trials ongoing.

• Strong intellectual property protection through 2042 and experienced leadership with prior success in rituximab and ibrutinib.

• Pipeline expansion planned across dermatology, pulmonology, gastroenterology, and rheumatology.

Mechanism of action and scientific rationale

• Soquelitinib blocks ITK, modulating Th2 and Th17 pathways, reducing inflammatory cytokines and rebalancing immune response.

• ITK inhibition increases regulatory T cells (Tregs) and decreases Th17, supporting durable immune modulation.

• Highly selective for ITK compared to other kinases, minimizing off-target effects.

• Biomarker data confirm reduction in Th2 cells, IL-4, IL-5, and IL-17, consistent with the proposed mechanism.

Clinical efficacy and safety in atopic dermatitis

• Phase 1 AD trial showed 75% of patients achieved EASI 75, 25% achieved EASI 90, and 33% reached IGA 0/1 after 8 weeks.

• Efficacy was consistent in patients with prior systemic therapy, including those resistant to other treatments.

• Durable remission observed post-treatment, with increased Tregs and immune rebalancing.

• Safety profile was strong, with no severe or serious adverse events and similar rates of mild AEs compared to placebo.